type 2 diabetes

Millions of patients are now taking drugs like Ozempic and Wegovy, but clinicians still struggle to predict who will benefit and how best to support lasting results.

Eli Lilly’s oral orforglipron and Novo Nordisk’s higher-dose WeGovy could be approved on an extremely accelerated timeline. 

Explore the mechanisms, clinical applications, and future opportunities of GLP-1 receptor agonists in drug development and disease management.

With blockbuster status secured, GLP-1 therapies face new questions about efficacy, delivery, and their role in treating multiple chronic diseases.

Researchers showed that in rodent models, a glia-produced molecule could regulate weight loss and glucose metabolism without gastrointestinal symptoms.

Lifestyle and genetics intertwine to shape individual risk and the pathway to prediabetes reversal.

Targeting a gut microbial enzyme could potentially improve treatment for type 2 diabetes.